loading...| Preferred Name |
tesamorelin |
| ID |
http://purl.obolibrary.org/obo/dinto_DB08869 |
| ATCCode |
H01AC06 |
| binds | |
| CASRN |
901758-09-6 |
| DBBrand |
egrifta |
| DBSynonym |
tesamorelin acetate egrifta th9507 th-9507 acetate n-(trans-3-hexenoyl)-human growth hormone releasing factor (1-44) acetate th-9507 nda 22-505 |
| Definition |
Tesamorelin is a stabilized synthetic peptide analogue of the hypothalamic peptide, Growth Hormone Releasing Hormone (GHRH) indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Lipodystrophy is a metabolic condition characterized by insulin resistance, fat redistribution, and hyperlipidemia associated with antiretroviral therapy for HIV infection. |
| has pharmacological target | |
| label |
tesamorelin |
| prefixIRI |
obo2:dinto_DB08869 |
| prefLabel |
tesamorelin |
| xref |
National Drug Code Directory:44087-2010-3 UniProtKB:P01286 ChEBI:63626 RxList:http://www.rxlist.com/egrifta-drug.htm PDRhealth:http://www.pdr.net/drug-summary/egrifta?druglabeli Drugs.com:http://www.drugs.com/egrifta.html Wikipedia:http://en.wikipedia.org/wiki/Tesamorelin |
| subClassOf |